Journal of Vascular Surgery
Volume 45, Issue 6, Supplement , Pages A82-A91 , June 2007

Genomic and proteomic determinants of lower extremity revascularization failure: Rationale and study design

Received 4 January 2007 ,Accepted 6 March 2007.

References 

  1. Dalman RL, Taylor LM. Basic data related to infrainguinal revascularization procedures. Ann Vasc Surg. 1990;4:309–312
  2. Lam EY, Williamson WK, Nicoloff AD, Porter JM. Distal bypass: is it effective for limb salvage?. Adv Surg. 2000;34:383–392
  3. Chew DK, Conte MS, Belkin M, Donaldson MC, Whittemore AD. Arterial reconstruction for lower limb ischemia. Acta Chir Belg. 2001;101:106–115
  4. Dougherty MJ, Calligaro KD, DeLaurentis DA. The natural history of “failing” arterial bypass grafts in a duplex surveillance protocol. Ann Vasc Surg. 1998;12:255–259
  5. Gupta AK, Bandyk DF, Cheanvechai D, Johnson BL. Natural history of infrainguinal vein graft stenosis relative to bypass grafting technique. J Vasc Surg. 1997;25:211–220discussion 220-5
  6. Mills JL, Wixon CL, James DC, Devine J, Westerband A, Hughes JD. The natural history of intermediate and critical vein graft stenosis: recommendations for continued surveillance or repair. J Vasc Surg. 2001;33:273–278discussion 278-80
  7. Conte MS, Bandyk DF, Clowes AW, Moneta GL, Seely L, Lorenz TJ, et al. Results of PREVENT III: a multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery. J Vasc Surg. 2006;43:742–751discussion 751
  8. Borozan PG, Schuler JJ, Spigos DG, Flanigan DP. Long-term hemodynamic evaluation of lower extremity percutaneous transluminal angioplasty. J Vasc Surg. 1985;2:785–793
  9. Surowiec SM, Davies MG, Eberly SW, Rhodes JM, Illig KA, Shortell CK, et al. Percutaneous angioplasty and stenting of the superficial femoral artery. J Vasc Surg. 2005;41:269–278
  10. Harris RW, Dulawa LB, Andros G, Oblath RW, Salles-Cunha SX, Apyan RL. Percutaneous transluminal angioplasty of the lower extremities by the vascular surgeon. Ann Vasc Surg. 1991;5:345–353
  11. Murphy TP. Medical outcomes studies in peripheral vascular disease. J Vasc Interv Radiol. 1998;9:879–889
  12. Donnelly R. Assessment and management of intermittent claudication: importance of secondary prevention. Int J Clin Pract Suppl. 2001;2–9
  13. Hiatt WR. Medical treatment of peripheral arterial disease and claudication. N Engl J Med. 2001;344:1608–1621
  14. Nicoloff AD, Taylor LM, McLafferty RB, Moneta GL, Porter JM. Patient recovery after infrainguinal bypass grafting for limb salvage. J Vasc Surg. 1998;27:256–263discussion 264-6
  15. Taylor SM, Kalbaugh CA, Blackhurst DW, Cass AL, Trent EA, Langan EM, et al. Determinants of functional outcome after revascularization for critical limb ischemia: an analysis of 1000 consecutive vascular interventions. J Vasc Surg. 2006;44:747–755discussion 755-6
  16. Keefer A, Davies MG, Illig KA. Can endovascular therapy of infrainguinal disease for claudication be justified?. Expert Rev Cardiovasc Ther. 2004;2:229–237
  17. Aquarius AE, Denollet J, Hamming JF, Breek JC, De Vries J. Impaired health status and invasive treatment in peripheral arterial disease: a prospective 1-year follow-up study. J Vasc Surg. 2005;41:436–442
  18. Brothers TE, Cox MH, Robison JG, Elliott BM, Nietert P. Prospective decision analysis modeling indicates that clinical decisions in vascular surgery often fail to maximize patient expected utility. J Surg Res. 2004;120:278–287
  19. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med. 1999;340:115–126
  20. Hoch JR, Stark VK, van Rooijen N, Kim JL, Nutt MP, Warner TF. Macrophage depletion alters vein graft intimal hyperplasia. Surgery. 1999;126:428–437
  21. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685–1695
  22. Tanaka T, Ozaki K. Inflammation as a risk factor for myocardial infarction. J Hum Genet. 2006;51:595–604
  23. Libby P, Ridker PM. Novel inflammatory markers of coronary risk: theory versus practice. Circulation. 1999;100:1148–1150
  24. Barth A, Hare J. The potential for the transcriptome to serve as a clinical biomarker for cardiovascular diseases. Circ Res. 2006;98:1459–1461
  25. Cobb JP, Mindrinos MN, Miller-Graziano C, Calvano SE, Baker HV, Xiao W, et al. Application of genome-wide expression analysis to human health and disease. Proc Natl Acad Sci U S A. 2005;102:4801–4806
  26. Arrell DK, Neverova I, Van Eyk JE. Cardiovascular proteomics: evolution and potential. Circ Res. 2001;88:763–773
  27. Rubin EM, Tall A. Perspectives for vascular genomics. Nature. 2000;407:265–269
  28. Lenfant C. NHLBI genomics initiatives: looking beyond the human genome project. Circulation. 2000;101:468–469
  29. Wang L, Fan C, Topol SE, Topol EJ, Wang Q. Mutation of MEF2A in an inherited disorder with features of coronary artery disease. Science. 2003;302:1578–1581
  30. Yamada Y, Izawa H, Ichihara S, Takatsu F, Ishihara H, Hirayama H, et al. Prediction of the risk of myocardial infarction from polymorphisms in candidate genes. N Engl J Med. 2002;347:1916–1923
  31. Helgadottir A, Manolescu A, Thorleifsson G, Gretarsdottir S, Jonsdottir H, Thorsteinsdottir U, et al. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet. 2004;36:233–239
  32. Helgadottir A, Manolescu A, Helgason A, Thorleifsson G, Thorsteinsdottir U, Gudbjartsson DF, et al. A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction. Nat Genet. 2006;38:68–74
  33. Ozaki K, Inoue K, Sato H, Ohnishi Y, Sekine A, Sato H, et al. Functional variation in LGALS2 confers risk of myocardial infarction and regulates lymphotoxin-alpha secretion in vitro. Nature. 2004;429:72–75
  34. Chasman DI, Posada D, Subrahmanyan L, Cook NR, Stanton VP, Ridker PM. Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA. 2004;291:2821–2827
  35. Gerdes LU, Gerdes C, Kervinen K, Savolainen M, Klausen IC, Hansen PS, et al. The apolipoprotein epsilon4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction: a substudy of the Scandinavian simvastatin survival study. Circulation. 2000;101:1366–1371
  36. Mialet Perez J, Rathz DA, Petrashevskaya NN, Hahn HS, Wagoner LE, Schwartz A, et al. Beta 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nat Med. 2003;9:1300–1305
  37. Higashi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srinouanprachanh L, Farin FM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA. 2002;287:1690–1698
  38. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med. 2005;352:2285–2293
  39. Sabatine MS, Seidman JG, Seidman CE. Cardiovascular genomics. Circulation. 2006;113:e450–e455
  40. Weng L, Kavaslar N, Ustaszewska A, Doelle H, Schackwitz W, Hebert S, et al. Lack of MEF2A mutations in coronary artery disease. J Clin Invest. 2005;115:1016–1020
  41. Ganesh SK, Skelding KA, Mehta L, O’Neill K, Joo J, Zheng G, et al. Rationale and study design of the CardioGene Study: genomics of in-stent restenosis. Pharmacogenomics. 2004;5:952–1004
  42. Dormandy JA, Rutherford RB. Management of peripheral arterial disease (PAD) (TASC Working Group. TransAtlantic Inter-Society Concensus (TASC)). J Vasc Surg. 2000;31:S1–S296
  43. Rutherford RB, Baker JD, Ernst C, Johnston KW, Porter JM, Ahn S, et al. Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg. 1997;26:517–538
  44. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg. 2007;33(suppl 1):S1–S75
  45. Hiatt WR. Pharmacologic therapy for peripheral arterial disease and claudication. J Vasc Surg. 2002;36:1283–1291
  46. Daskalopoulou SS, Daskalopoulos ME, Liapis CD, Mikhailidis DP. Peripheral arterial disease: a missed opportunity to administer statins so as to reduce cardiac morbidity and mortality. Curr Med Chem. 2005;12:443–452
  47. Grundy SM, Cleeman JI, Merz CN, Brewer HB, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227–239
  48. Lazaris AM, Tsiamis AC, Fishwick G, Bolia A, Bell PR. Clinical outcome of primary infrainguinal subintimal angioplasty in diabetic patients with critical lower limb ischemia. J Endovasc Ther. 2004;11:447–453
  49. Nadal LL, Cynamon J, Lipsitz EC, Bolia A. Subintimal angioplasty for chronic arterial occlusions. Tech Vasc Interv Radiol. 2004;7:16–22
  50. Bolia A, Brennan J, Bell PR. Recanalisation of femoro-popliteal occlusions: improving success rate by subintimal recanalisation. Clin Radiol. 1989;40:325
  51. Ingle H, Nasim A, Bolia A, Fishwick G, Naylor R, Bell PR, et al. Subintimal angioplasty of isolated infragenicular vessels in lower limb ischemia: long-term results. J Endovasc Ther. 2002;9:411–416
  52. Varty K, Bolia A, Naylor AR, Bell PR, London NJ. Infrapopliteal percutaneous transluminal angioplasty: a safe and successful procedure. Eur J Vasc Endovasc Surg. 1995;9:341–345
  53. Bolia A, Sayers RD, Thompson MM, Bell PR. Subintimal and intraluminal recanalisation of occluded crural arteries by percutaneous balloon angioplasty. Eur J Vasc Surg. 1994;8:214–219
  54. Muradin GS, Bosch JL, Stijnen T, Hunink MG. Balloon dilation and stent implantation for treatment of femoropopliteal arterial disease: meta-analysis. Radiology. 2001;221:137–145
  55. Sarac TP, Huber TS, Back MR, Ozaki CK, Carlton LM, Flynn TC, et al. Warfarin improves the outcome of infrainguinal vein bypass grafting at high risk for failure. J Vasc Surg. 1998;28:446–457
  56. McDermott MM, Liu K, Ferrucci L, Criqui MH, Greenland P, Guralnik JM, et al. Physical performance in peripheral arterial disease: a slower rate of decline in patients who walk more. Ann Intern Med. 2006;144:10–20
  57. Montgomery PS, Gardner AW. The clinical utility of a six-minute walk test in peripheral arterial occlusive disease patients. J Am Geriatr Soc. 1998;46:706–711
  58. McHorney CA, Ware JE, Lu JF, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36): III (Tests of data quality, scaling assumptions, and reliability across diverse patient groups). Med Care. 1994;32:40–66
  59. Morgan MB, Crayford T, Murrin B, Fraser SC. Developing the Vascular Quality of Life Questionnaire: a new disease-specific quality of life measure for use in lower limb ischemia. J Vasc Surg. 2001;33:679–687
  60. Feezor RJ, Baker HV, Mindrinos M, Hayden D, Tannahill CL, Brownstein BH, et al. Whole blood and leukocyte RNA isolation for gene expression analyses. Physiol Genomics. 2004;19:247–254
  61. Laudanski K, Miller-Graziano C, Xiao W, Mindrinos MN, Richards DR, De A, et al. Cell-specific expression and pathway analyses reveal alterations in trauma-related human T cell and monocyte pathways. Proc Natl Acad Sci USA. 2006;103:15564–15569
  62. Feezor RJ, Baker HV, Xiao W, Lee WA, Huber TS, Mindrinos M, et al. Genomic and proteomic determinants of outcome in patients undergoing thoracoabdominal aortic aneurysm repair. J Immunol. 2004;172:7103–7109
  63. Moe TK, Ziliang J, Barathi A, Beuerman RW. Differential expression of glyceraldehyde-3-phosphate dehydrogenase (GAPDH), beta actin and hypoxanthine phosphoribosyltransferase (HPRT) in postnatal rabbit sclera. Curr Eye Res. 2001;23:44–50
  64. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA. 1998;95:14863–14868
  65. Holter NS, Mitra M, Maritan A, Cieplak M, Banavar JR, Fedoroff NV. Fundamental patterns underlying gene expression profiles: simplicity from complexity. Proc Natl Acad Sci USA. 2000;97:8409–8414
  66. Doniger SW, Salomonis N, Dahlquist KD, Vranizan K, Lawlor SC, Conklin BR. MAPPFinder: using Gene Ontology and GenMAPP to create a global gene-expression profile from microarray data. Genome Biol. 2003;4:R7
  67. Dahlquist KD, Salomonis N, Vranizan K, Lawlor SC, Conklin BR. GenMAPP, a new tool for viewing and analyzing microarray data on biological pathways. Nat Genet. 2002;31:19–20
  68. Rajagopalan D, Agarwal P. Inferring pathways from gene lists using a literature-derived network of biological relationships. Bioinformatics. 2005;21:788–793
  69. Tavazoie S, Hughes JD, Campbell MJ, Cho RJ, Church GM. Systematic determination of genetic network architecture. Nat Genet. 1999;22:281–285
  70. Storey JD, Xiao W, Leek JT, Tompkins RG, Davis RW. Significance analysis of time course microarray experiments. Proc Natl Acad Sci USA. 2005;102:12837–12842
  71. Spellman PT, Sherlock G, Zhang MQ, Iyer VR, Anders K, Eisen MB, et al. Comprehensive identification of cell cycle-regulated genes of the yeast Saccharomyces cerevisiae by microarray hybridization. Mol Biol Cell. 1998;9:3273–3297
  72. Hitchcock D, Casella G, Booth J. Improved estimation of dissimilarities by presmoothing functional data. J Am Stat Assoc. 2006;101:211–222
  73. Ramsay JO, Spellman BW. Functional data analysis. New York: Springer-Verlag; 1997;
  74. Ramsay JO, Spellman BW. Applied functional data analysis: methods and case studies. New York: Springer-Verlag; 2002;
  75. Luan Y, Li H. Clustering of time-course gene expression data using a mixed-effects model with B-splines. Bioinformatics. 2003;19:474–482
  76. Fong YM, Marano MA, Moldawer LL, Wei H, Calvano SE, Kenney JS, et al. The acute splanchnic and peripheral tissue metabolic response to endotoxin in humans. J Clin Invest. 1990;85:1896–1904

 Competition of interest: none.This work was supported in part by NHLBI grant 1K23HL084090-01 (P. R. N.) and NIGMS grant 2T32GM08721-06 (K. A.O.).

PII: S0741-5214(07)00449-1

doi: 10.1016/j.jvs.2007.03.011

Journal of Vascular Surgery
Volume 45, Issue 6, Supplement , Pages A82-A91 , June 2007

Article Tools

* Image Usage & Resolution